Connection

MICHELE REDELL to Cell Line, Tumor

This is a "connection" page, showing publications MICHELE REDELL has written about Cell Line, Tumor.
Connection Strength

0.329
  1. Aberrantly low STAT3 and STAT5 responses are associated with poor outcome and an inflammatory gene expression signature in pediatric acute myeloid leukemia. Clin Transl Oncol. 2021 Oct; 23(10):2141-2154.
    View in: PubMed
    Score: 0.113
  2. Stromal CYR61 Confers Resistance to Mitoxantrone via Spleen Tyrosine Kinase Activation in Human Acute Myeloid Leukaemia. Br J Haematol. 2015 Sep; 170(5):704-18.
    View in: PubMed
    Score: 0.075
  3. Modulating TNFa activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia. J Immunother Cancer. 2020 09; 8(2).
    View in: PubMed
    Score: 0.027
  4. Targeting STAT3 anti-apoptosis pathways with organic and hybrid organic-inorganic inhibitors. Org Biomol Chem. 2020 05 06; 18(17):3288-3296.
    View in: PubMed
    Score: 0.026
  5. Atovaquone is active against AML by upregulating the integrated stress pathway and suppressing oxidative phosphorylation. Blood Adv. 2019 12 23; 3(24):4215-4227.
    View in: PubMed
    Score: 0.026
  6. Glucocorticoids Inhibit Oncogenic RUNX1-ETO in Acute Myeloid Leukemia with Chromosome Translocation t(8;21). Theranostics. 2018; 8(8):2189-2201.
    View in: PubMed
    Score: 0.023
  7. CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia. Mol Ther. 2016 09 29; 24(9):1615-26.
    View in: PubMed
    Score: 0.020
  8. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia. J Hematol Oncol. 2016 Mar 12; 9:24.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.